Last reviewed · How we verify
FLOT
FLOT is a chemotherapy regimen combining fluorouracil, leucovorin, oxaliplatin, and docetaxel to inhibit DNA synthesis and microtubule formation, killing rapidly dividing cancer cells.
FLOT is a chemotherapy regimen combining fluorouracil, leucovorin, oxaliplatin, and docetaxel to inhibit DNA synthesis and microtubule formation, killing rapidly dividing cancer cells. Used for Metastatic or locally advanced gastric cancer, Gastroesophageal junction adenocarcinoma, Perioperative treatment of resectable gastric cancer.
At a glance
| Generic name | FLOT |
|---|---|
| Sponsor | European Organisation for Research and Treatment of Cancer - EORTC |
| Drug class | Chemotherapy regimen (combination) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
FLOT is a polychemotherapy combination where fluorouracil and leucovorin inhibit thymidylate synthase to disrupt DNA synthesis, oxaliplatin creates DNA cross-links, and docetaxel stabilizes microtubules to prevent cell division. This multi-agent approach targets cancer cells through complementary mechanisms of action, commonly used in gastric and gastroesophageal junction cancers.
Approved indications
- Metastatic or locally advanced gastric cancer
- Gastroesophageal junction adenocarcinoma
- Perioperative treatment of resectable gastric cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Diarrhea
- Mucositis
- Peripheral neuropathy
- Fatigue
Key clinical trials
- Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity (PHASE2, PHASE3)
- A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (PHASE2)
- Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) (PHASE1)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) (PHASE3)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension (PHASE3)
- Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (PHASE2, PHASE3)
- Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma (PHASE2)
- A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FLOT CI brief — competitive landscape report
- FLOT updates RSS · CI watch RSS
- European Organisation for Research and Treatment of Cancer - EORTC portfolio CI